IOVA— IOVANCE BIOTHERAPEUTICS, INC.

MaterialsBiotechnology$2.9B mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Total revenue	$263.5M+60.6%	$164.1M+13699.0%	$1.2M	—
Cost of sales	$173.2M+85.7%	$93.2M+8926.9%	$1.0M	—
Research and development	$300.3M+8.7%	$276.2M-17.1%	$333.2M+13.0%	$294.8M
Selling, general, and administrative	$152.3M+0.0%	$152.3M+43.5%	$106.1M+1.9%	$104.1M
Depreciation and amortization	$35.9M-4.4%	$37.6M+75.5%	$21.4M	—
Restructuring charges	$5.1M	—	—	—
Total costs and expenses	$666.9M+19.2%	$559.3M+21.1%	$461.7M+15.8%	$398.9M
Loss from operations	-$403.4M-2.0%	-$395.3M+14.2%	-$460.6M-15.5%	-$398.9M
Interest and other income, net	$10.3M-49.2%	$20.3M+55.4%	$13.0M+337.0%	$3.0M
Net Loss before income taxes	-$393.0M-4.8%	-$375.0M+16.2%	-$447.5M-13.0%	-$395.9M
Income tax (expense) benefit	$2.1M-26.8%	$2.8M-18.7%	$3.5M	$0
Net Loss	-$391.0M-5.1%	-$372.2M+16.2%	-$444.0M-12.2%	-$395.9M
Net Loss Per Share of Common Stock, Basic (in dollars per share)	-$1.09+14.8%	-$1.28+32.3%	-$1.89+24.1%	-$2.49
Net Loss Per Share of Common Stock, Diluted (in dollars per share)	-$1.09+14.8%	-$1.28+32.3%	-$1.89+24.1%	-$2.49
Weighted Average Shares of Common Stock Outstanding, Basic (in shares)	357.3M+23.3%	289.9M+23.3%	235.1M+47.6%	159.3M
Weighted Average Shares of Common Stock Outstanding, Diluted (in shares)	357.3M+23.3%	289.9M+23.3%	235.1M+47.6%	159.3M
Non-cash stock-based compensation included in cost of sales	$7.3M-14.8%	$8.6M	—	—
Non-cash stock-based compensation included in research and development	$27.0M-45.3%	$49.3M+41.1%	$34.9M	—
Non-cash stock-based compensation included in selling, general and administrative	$27.3M-47.2%	$51.8M+87.0%	$27.7M	—
Share-based Compensation	$61.6M-43.8%	$109.6M+75.0%	$62.6M	—

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 13 more years of annual history and full quarterly detail on Pro.

Upgrade to Pro →

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.